These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
151 related articles for article (PubMed ID: 1686720)
1. The role of metallothioneins in anticancer drug resistance. Bahnson RR; Basu A; Lazo JS Cancer Treat Res; 1991; 57():251-60. PubMed ID: 1686720 [No Abstract] [Full Text] [Related]
2. Modulation of antitumor alkylating agents (AA). Teicher BA; Frei E Cancer Treat Res; 1991; 57():261-95. PubMed ID: 1686721 [No Abstract] [Full Text] [Related]
3. Metallothionein expression and transient resistance to electrophilic antineoplastic drugs. Lazo JS; Basu A Semin Cancer Biol; 1991 Aug; 2(4):267-71. PubMed ID: 1912530 [TBL] [Abstract][Full Text] [Related]
4. Metallothionein and anticancer agents: the role of metallothionein in cancer chemotherapy. Doz F; Roosen N; Rosenblum ML J Neurooncol; 1993 Aug; 17(2):123-9. PubMed ID: 8145055 [TBL] [Abstract][Full Text] [Related]
7. Protective function of metallothionein against certain anticancer agents. Endresen L; Rugstad HE Experientia Suppl; 1987; 52():595-602. PubMed ID: 2959550 [TBL] [Abstract][Full Text] [Related]
9. Capturing platinum in cisplatin: kinetic reactions with recombinant human apo-metallothionein 1a. Wong DL; Stillman MJ Metallomics; 2018 May; 10(5):713-721. PubMed ID: 29687824 [TBL] [Abstract][Full Text] [Related]
10. Cisplatin. Reed E Cancer Chemother Biol Response Modif; 1990; 11():90-6. PubMed ID: 2223411 [No Abstract] [Full Text] [Related]
11. A hypothesis regarding the protective role of metallothioneins against the toxicity of DNA interactive anticancer drugs. Basu A; Lazo JS Toxicol Lett; 1990 Feb; 50(2-3):123-35; discussion 121-2. PubMed ID: 2408195 [TBL] [Abstract][Full Text] [Related]
13. Altered cisplatin and cadmium resistance and cell survival in Chinese hamster ovary cells expressing mouse metallothionein. Koropatnick J; Pearson J Mol Pharmacol; 1993 Jul; 44(1):44-50. PubMed ID: 8341278 [TBL] [Abstract][Full Text] [Related]
14. Mechanisms of acquired resistance to cisplatin. Andrews PA Cancer Treat Res; 1994; 73():217-48. PubMed ID: 7710906 [No Abstract] [Full Text] [Related]
15. Metallothionein gene expression and resistance to cisplatin in human ovarian cancer. Schilder RJ; Hall L; Monks A; Handel LM; Fornace AJ; Ozols RF; Fojo AT; Hamilton TC Int J Cancer; 1990 Mar; 45(3):416-22. PubMed ID: 2307530 [TBL] [Abstract][Full Text] [Related]
16. Metallothioneins and resistance to cisplatin and radiation in prostate cancer. Smith DJ; Jaggi M; Zhang W; Galich A; Du C; Sterrett SP; Smith LM; Balaji KC Urology; 2006 Jun; 67(6):1341-7. PubMed ID: 16765200 [TBL] [Abstract][Full Text] [Related]
19. Long noncoding RNAs as biotargets in cisplatin-based drug resistance. Abu N; Hon KW; Jeyaraman S; Jamal R Future Oncol; 2018 Dec; 14(29):3085-3095. PubMed ID: 30468082 [TBL] [Abstract][Full Text] [Related]
20. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines. Teicher BA; Cucchi CA; Lee JB; Flatow JL; Rosowsky A; Frei E Cancer Res; 1986 Sep; 46(9):4379-83. PubMed ID: 3731096 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]